Skip To Main Content
Kandolf-Sekulovic L on Muck Rack

Kandolf-Sekulovic L

Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Kandolf-Sekulovic

Contact Kandolf-Sekulovic, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial - PubMed

|
By Eigentler TK, Kandolf-Sekulovic L, Terheyden PAM, Gesierich AH
| ncbi.nlm.nih.gov
Skip to main page content Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software doi: 10.1016/j.ejca.2023.112941. Online ahead of print.
Open in Who Shared Issue with article?
See all 1 articles